preloader
preloader
Press Releases

In the press.

Coverage of Vamstar's product launches, partnerships, and conference appearances. For media enquiries, write to marketing@vamstar.io.

Latest
London 5 October 2026
Award Notice

Vamstar wins £900k ($1.2M) Innovate UK Sovereign AI award to show health technology developers what payers will accept before trial designs are locked

Vamstar, a London-based life sciences AI company, has secured £900k ($1.2M) through Innovate UK’s Sovereign AI programme, which funded only the top 1% of applications. The award will support a UK-owned AI platform that helps health technology developers anticipate payer requirements and predict launch outcomes before trial protocols are locked. Over the next 12 months, the funding will take the technology from a validated proof of concept to a working demonstrator in a real-world environment.

Global pharmaceutical R&D spending exceeds £200 billion ($264 billion) a year, yet most candidates that reach late-stage trials never become commercially viable. Evidence strategy and pricing assumptions are set at trial design, often years before bodies such as NICE decide whether the evidence justifies the price. By the time a payer identifies a gap, the trial can no longer change. Patients wait longer, health systems face slower and costlier access decisions, and developers lose value they could have kept.

Vamstar’s platform brings payer intelligence into the design stage. Its agentic AI architecture connects clinical trial evidence, health-economic modelling and real-world market and pricing data in one system, showing development teams which evidence payers will expect, what price it will support, and which design choices give the best chance of market access. In an earlier Innovate UK-funded proof of concept, Vamstar automated HTA evidence retrieval and health-economic modelling, reproducing published NICE cost-effectiveness results with over 90% consistency. The demonstrator will extend coverage to six therapeutic areas, add new clinical, outcomes and market data sources, and run at scale as a cloud service. Every output links back to its source evidence, and the system runs on UK infrastructure in line with NICE methods.

“The industry spends years generating evidence and only learns at the end whether payers will accept it. We are reversing that order,” said Praful Mehta, CEO and co-founder of Vamstar. “If developers can see the market-access verdict while the trial can still change, they design better trials, fewer good products fail for the wrong reasons, and patients get them sooner.”

Vamstar is inviting a small number of pharmaceutical, biotech, medtech and NHS organisations to shape early deployment. Teams preparing HTA submissions or making late-stage development decisions can register interest at timothy.farnham@vamstar.io.

PRESSAT
— Earlier releases

  • Vamstar Launches Forward Deployed Engineering for Healthcare Commercial AI in Partnership with Kaktus Technologies.

    New capability brings agentic AI, regulated cloud engineering, and embedded delivery pods into Pharma, MedTech, and Biotech commercial workflows

    Vamstar today announced the launch of Vamstar Forward Deployed Engineering for Healthcare Commercial AI, a new deployment capability designed to help Pharma, MedTech, and Biotech organisations move AI from pilots and slideware into production-grade commercial operations.

    Developed in partnership with Kaktus Technologies, the capability combines Vamstar’s Polaris agentic AI technology for life sciences commercial workflows with Kaktus’s regulated cloud and AI engineering expertise across AWS, Azure, and Google Cloud Platform.

    The launch addresses a persistent challenge across healthcare commercial transformation: AI models are no longer the primary bottleneck. The barrier to operational impact is increasingly found in the surrounding delivery environment, including workflow design, secure deployment, MLOps, auditability, data governance, and the ability to embed engineering teams directly inside regulated enterprise workflows.

    “Software is the easy part. Deployment is the moat,” said Praful Mehta, CEO at Vamstar. “The models work. They have for a while. What has held commercial AI back in Medtech and Pharma is everything around the model: the workflows, the infrastructure, the governance, and the operational reality of deploying inside complex, regulated organisations. Forward Deployed Engineering changes that model by putting expert pods inside the customer from week one.”

    Vamstar Forward Deployed Engineering is designed around embedded delivery pods that work directly with customer stakeholders, systems, and workflows. The capability supports two core deployment modes: Agentic Operations, focused on regulated commercial workflows such as tender discovery, product matching, RFx response, contract lifecycle management, and commercial intelligence; and Applied Data Science, focused on quantitative AI products such as revenue excellence, demand forecasting, clinical value mapping, price-value prediction, and supply chain risk.

    The partnership brings together complementary strengths. Vamstar contributes deep domain expertise across life sciences commercial operations, including tendering, pricing, contracting, market access, MEAT, GPO, and country-by-country procurement. Kaktus Technologies contributes cloud and AI engineering rigour, with experience building enterprise-grade automation environments hardened for healthcare, compliance, and regulated enterprise scale.

    Together, the offering is designed to provide UK and EU depth with North American reach, supporting customers operating across complex commercial, regulatory, and procurement environments.

    Unlike traditional SaaS implementations or consulting-led transformation programmes, Vamstar Forward Deployed Engineering is structured around rapid, production-oriented deployment. A pod is embedded into the customer workflow in week one, with a lighthouse engagement targeted for production in 8 to 14 weeks. The focus is on measurable outcomes, including improved commercial contract win rates, reduced contract cycle times, faster revenue acceleration, and improved net price realisation.

    “Healthcare commercial AI cannot succeed as a login, a roadmap, or another disconnected dashboard,” said Naveen Bhardwaj, COO at Kaktus Technologies, WA Seattle. “It needs secure infrastructure, cloud-native MLOps, enterprise integration, and engineers who understand what it takes to operate inside regulated environments. This partnership brings those capabilities together with Vamstar’s deep commercial AI expertise.”

    The new capability is aimed at Pharma and MedTech commercial leaders whose tendering, contracting, pricing, or market access workflows are constrained by fragmented systems, manual processes, stalled pilots, or enterprise deployment complexity. It is particularly suited to organisations seeking production outcomes within two quarters rather than extended transformation timelines.

    Vamstar Forward Deployed Engineering expands the company’s existing Polaris AI platform strategy by adding an embedded delivery model for customers that need deeper implementation support, tailored workflow design, and production-grade operational integration.

    “The age of life-sciences-by-PowerPoint is over,” added Tim Farnham, Director of Marketing at Vamstar. “The next phase of healthcare commercial AI will belong to organisations that can deploy, govern, and scale AI inside the work itself. That is what this launch is built to deliver.”

    MedTech Dive

  • Vamstar, the global leader in AI-powered commercialization solutions for life sciences, has announced the official launch of its U.S.-specific RFP AI platform. This new solution is designed to transform how MedTech companies compete for high-value contracts across the American healthcare system. The launch coincides with the opening of The MedTech Conference by AdvaMed in San Diego, one of the leading gatherings for executives shaping the future of healthcare technology.

    The U.S. commercialization and procurement environment remains fragmented, compliance-heavy, and fiercely competitive. Every year, billions of dollars in contracts flow through federal systems such as SAM.gov, VA/DoD, as well as state and local agencies, hospital systems, and GPOs. Despite the size of the market, many MedTech suppliers continue to miss critical opportunities or struggle with complex compliance requirements, repetitive submissions, and lengthy review cycles.

     

    Vamstar’s new U.S. RFP AI addresses these challenges directly. The platform delivers full-spectrum discovery by scanning every U.S. procurement channel in real time, from federal portals to GPOs and IDNs. Compliance is built-in, embedding FDA, ISO, cybersecurity, and supply chain resilience documentation into every proposal. Cycle times are significantly reduced, with AI-driven drafting and collaboration tools accelerating RFQ and RFP responses by up to 50%. The platform also introduces smarter prioritization, ranking opportunities by fit, margin impact, and probability of success.

    “Generic proposal platforms don’t meet the demands of MedTech in the United States,” said Praful Mehta, CEO of Vamstar. “Our RFP AI is healthcare-native by design. It gives commercial teams the visibility, speed, and compliance confidence they need to win more contracts and protect margins in a tightening market.”

    Vamstar’s leadership team will be present in San Diego during the conference to provide exclusive, one-on-one demonstrations of the new platform for select MedTech executives.

    View original on newswiretoday.com

  • Vamstar made a commanding appearance at the MedTech Forum 2025 in Lisbon, showcasing its bold vision for how artificial intelligence will redefine the future of healthcare commercialization. As a recognized leader in AI-powered solutions for the life sciences industry, Vamstar highlighted how its advanced platforms are helping MedTech organizations streamline operations, enhance market access, and unlock new growth opportunities.

    During the event, Vamstar’s team engaged with global industry leaders to demonstrate how its Agentic AI technology integrates data, automates critical processes, and delivers real-time intelligence that drives smarter, faster decisions. The company emphasized that AI is no longer a distant concept but an immediate catalyst for efficiency and competitiveness, capable of transforming pricing strategies, tender management, and value-based procurement across the healthcare ecosystem.

    By sharing practical insights and future-focused strategies, Vamstar reinforced its commitment to empowering MedTech companies to navigate a rapidly evolving market. The Lisbon forum served as a platform to underline Vamstar’s role as an innovator and trusted partner for organizations seeking to leverage AI for sustainable growth and commercial excellence.

    View original on newsbywire.com

  • Vamstar’s Agentic AI is emerging as a pivotal force in helping MedTech and pharmaceutical companies navigate mounting economic pressures and industry disruption. Positioned as a next-generation commercial intelligence platform, Agentic AI equips organizations with the ability to integrate vast data sources, automate complex workflows, and uncover actionable insights that drive market access and pricing strategies.

    This transformative technology goes beyond traditional automation by acting as an adaptive partner in decision-making. It empowers commercial teams to anticipate market shifts, optimize tender and pricing operations, and respond rapidly to regulatory changes, all while maintaining precision and compliance. In an environment where efficiency and resilience are critical, Agentic AI provides a measurable advantage, enabling companies to safeguard profitability and scale sustainably.

    By redefining how life sciences organizations approach commercialization, Vamstar is setting a new benchmark for value creation. Agentic AI is not merely a tool—it is a strategic asset that strengthens competitiveness and ensures MedTech and pharma companies can thrive even in challenging economic climates.

    View original on pr.com

  • Vamstar has announced a strategic partnership with Pricia, a leading Nordic pricing consultancy, to redefine pharmaceutical pricing strategies across the Nordic region. This collaboration brings together Vamstar’s advanced AI Pricing Co-Pilot technology with Pricia’s deep expertise in market-specific pricing dynamics, creating a powerful alliance designed to transform how pharmaceutical companies approach price optimization and market access.

    By integrating Vamstar’s AI-driven insights with Pricia’s regional knowledge and proven methodologies, the partnership aims to streamline complex pricing processes, enhance forecasting accuracy, and enable data-backed decision-making for life sciences organizations. The combined solution is set to deliver a new standard of agility and precision, empowering pharmaceutical teams to respond quickly to market shifts while maintaining compliance and maximizing value.

    This joint initiative reflects both companies’ commitment to innovation and their shared vision of reshaping pricing strategies to meet the evolving demands of healthcare systems in the Nordics. Together, Vamstar and Pricia are poised to accelerate growth and unlock new opportunities for pharmaceutical manufacturers seeking competitive advantage in a highly regulated and rapidly changing market.

    View original on pr.com

  • Vamstar has unveiled TenderGPT, a breakthrough AI-powered platform built to redefine how pharmaceutical, medtech, healthcare, and life-science organizations manage tenders and RFPs. Officially launched in London in July 2024, the platform delivers a new standard for speed, accuracy, and insight—transforming a traditionally manual, time-intensive process into an intelligent, data-driven engine.

    At its core, TenderGPT consolidates global opportunity tracking, historical data, and real-time analytics into a single, secure environment. Teams can discover and monitor tenders in more than 100 countries, integrate past notices and awards with current market intelligence, and rely on automated document completion to respond quickly and confidently. Advanced “tender war-gaming” tools simulate competitive scenarios, helping organizations plan winning strategies while maintaining full control of sensitive information.

    By automating repetitive tasks and orchestrating critical data, TenderGPT empowers commercial and procurement teams to focus on strategic decision-making.

    The result is a step change in efficiency and accuracy, enabling life-sciences companies to capture more opportunities, reduce operational friction, and elevate tender management into a proactive, growth-driven function.

    View original on finance.yahoo.com
No releases for this year.